Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. Co. is utilizing its proprietary switch-control kinase inhibitor platform and capabilities in kinase biology to develop a portfolio of medicines. Co. has one approved drug, QINLOCK, which is for the treatment of adult patients with gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. Co. is also developing clinical-stage drug candidates, including vimseltinib (DCC-3014), which is an investigational and selective inhibitor of the colony stimulating factor 1 receptor. The DCPH stock yearly return is shown above.
The yearly return on the DCPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DCPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|